Medvantx

Targacept is a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat diseases and disorders of the central nervous system. It is a leader in the field of neuronal nicotinic acetylcholine receptor chemistry and biology. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity. Targacept s product candidates are designed to selectively target specific NNR subtypes and promote therapeutic effects and limit adverse side effects. Targacept has product candidates in clinical development for cognitive impairment, including Alzheimer s disease and age-associated memory impairment, pain and depression. From 1997 to 2000, Targacept was a subsidiary of R. J. Reynolds Tobacco Company. During this time, the company s investigations into the biological effects of nicotine suggested a role for NNRs in the treatment of human disease and led to the creation of Targacept.

ACADIA Pharmaceuticals is a biopharmaceutical company utilizing technology to fuel drug discovery and clinical development of treatments for central nervous system disorders. It has five drug programs in clinical and pre-clinical development directed at large unmet medical needs and major commercial markets. ACADIA s three Phase II-stage clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, ACP-103 as an adjunctive therapy for schizophrenia and ACP-104 for treatment of schizophrenia. The company also has clinical and pre-clinical development programs in the areas of neuropathic pain and glaucoma in collaboration with Allergan. ACADIA maintains headquarters and biology research facilities in San Diego and a chemistry research facility in Malmo, Sweden. It trades on NASDAQ under the symbol ACAD.